AstraZeneca shares tumbled nearly 5% on Monday while Bristol-Myers Squibb shares jumped 6% following reports by Reuters and Bloomberg about merger talks between the two pharmaceutical giants. These discussions, described as being at a preliminary stage, have raised questions among analysts about the rationale behind such a deal. If completed, this would be one of the biggest-ever deals in the global pharmaceutical sector.
Source: Read the original article
